Demand in the United States for influenza vaccines is expected to remain high over the coming decade.
U.S. demand began to spike following fears of the H1N1 pandemic. Seasonal influenza vaccine demand is expected to increase from the 142 million doses expected this season to 158 million in 2022. The business intelligence provider GlobalData expects a relatively consistent annual growth rate of 1.2 percent.
The H1N1, or swine flu, pandemic claimed thousands of live in the United States in 2009. It effectively fueled a significant rise of those in United States vaccinated every year. In 2007, 24 percent of Americans aged five-64 were vaccinated against the flu. In 2010, the number of vaccinated between the ages five-64 climbed to 41 percent, according to the U.S. Centers for Disease Control and Prevention.
The GlobalData vaccine report suggests that the general increase in the U.S. population and the corresponding rise in those classified as high-risk, the elderly and those with pre-existing conditions will drive the predicted growth in demand.
GlobalData also examined vaccine demand in eight other countries, including Japan, India, China and five of the European Union's top economies. India is expected to show the greatest growth in vaccine demand over the next decade, although few Indians overall are expected to receive the vaccination.